Natixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Natixis Advisors LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,300 shares of the company’s stock, valued at approximately $403,000.

Other hedge funds also recently modified their holdings of the company. Barclays PLC raised its position in Spyre Therapeutics by 64.7% during the 3rd quarter. Barclays PLC now owns 105,467 shares of the company’s stock worth $3,101,000 after purchasing an additional 41,424 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Spyre Therapeutics during the fourth quarter worth about $290,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Spyre Therapeutics by 239.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company’s stock worth $9,802,000 after acquiring an additional 235,094 shares during the period. Victory Capital Management Inc. bought a new stake in Spyre Therapeutics in the fourth quarter valued at approximately $6,241,000. Finally, Jane Street Group LLC lifted its position in shares of Spyre Therapeutics by 78.7% in the 3rd quarter. Jane Street Group LLC now owns 20,641 shares of the company’s stock worth $607,000 after purchasing an additional 9,090 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Trading Up 3.9 %

Shares of NASDAQ SYRE opened at $17.69 on Friday. The firm has a market capitalization of $1.07 billion, a P/E ratio of -2.37 and a beta of 2.98. The firm’s 50-day moving average price is $20.60 and its 200-day moving average price is $25.67. Spyre Therapeutics, Inc. has a 1-year low of $16.71 and a 1-year high of $40.84.

Spyre Therapeutics (NASDAQ:SYRE) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.08. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wolfe Research assumed coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Wedbush reissued an “outperform” rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a research report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Spyre Therapeutics presently has an average rating of “Buy” and an average target price of $50.33.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).